Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06672952 · ClinicalTrials.gov registry record · NA
Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators
A NA study of Cognitive Function and Exercise Performance, sponsored by Lindenwood University.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06672952: Recruiting NA study of Cognitive Function and Exercise Performance, sponsored by Lindenwood University.
NCT06672952 is a NA study of Cognitive Function and Exercise Performance that is actively recruiting participants, run by Lindenwood University. The registered enrollment target is 60 participants, below the 495-participant average among 20 other Cognitive Function trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06672952, a NA study of Cognitive Function and Exercise Performance, is actively recruiting participants, sponsored by Lindenwood University.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.
Primary Outcome
Peak VO2 will be measured as an indicator of maximal aerobic capacity. Higher values reflect improved cardiovascular performance.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT 400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation
- DIETARY_SUPPLEMENT 200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation
Study Locations (1)
Missouri
- Lindenwood University - Saint Charles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2026-01-01 |
| Phase | NA |
What NCT06672952 shows while recruiting
NCT06672952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 495-participant average among 20 other Cognitive Function trials with a reported enrollment target (88% lower).
The record links to 6 conditions, with Cognitive Function appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06672952 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06672952 about?
NCT06672952 is a clinical study titled "Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators". The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.
What is the current status of trial NCT06672952?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-04-15. Estimated completion is 2026-01-01.
What conditions does trial NCT06672952 study?
This clinical trial studies the following conditions: Cognitive Function, Exercise Performance, Nitric Oxide, Blood Flow, Exercise Recovery.
What interventions are being tested in trial NCT06672952?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), 400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation (DIETARY_SUPPLEMENT), 200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06672952?
This trial is sponsored by Lindenwood University, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06672952 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Function
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06672952's enrollment target sits among peer trials
60 12th of 20 higher than 9 of 20 other Cognitive Function trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Function trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brain Stimulation Effects on Cognitive Task Performance
RECRUITING · NA
-
Effect of Daily Mixed Spice Consumption on Memory Function
RECRUITING · NA
-
IMST for Dementia Risk Reduction
RECRUITING · NA
-
Radicle Clarity™ RBB: A Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes
RECRUITING · NA
-
Impact of a Novel Brain Longevity Supplement Containing the Postbiotic Urolithin A (Mitopure) on Cognitive Function and Related Health Outcomes
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI